This in vitro approach also supports prudent adoption of exposure control strategies protection of workers, consumers, and the environment.
The results show that the sample adoption rates – (joint exposure and adoption rate) is the same for the ATE probit, and the classic probit estimated at (14%%) and that they all yield the same range for the 95%% confidence interval (between 10% and 177 %).
The "treatment effect" for the farmer i is the measure by the difference y 1i - y 0i Hence the expected population adoption impact of exposure to the new varieties is given by the mean value E y 1 - y 0).
However, results are difficult to compare due to the adoption of alternative exposure definitions and to limitations in the analytical approaches.
aLogistic regression for the outcome of adoption, controlling for previous exposure to CRC studies (no exposure vs. previous exposure).
Note that as discussed earlier, the joint exposure and adoption parameter (JEA) is consistently estimated by the sample average of the observed adoption outcome values: ( Jwidehat{E}A=frac{1}{n}{displaystyle sum_{i=1}^n{y}_i} ).
These results, therefore, represent the expected joint exposure and adoption rate for the population which is not the desirable parameter of interest in most adoption studies.
GSMA supports adoption of WHO-recommended exposure limits and continuing actions to ensure the public has access to accurate information.
The adoption of a shared exposure protocol by the research community is strongly recommended since it is a key aspect to make biomonitoring surveys directly comparable, also in view of its recognition as a monitoring method by the EU legislation.
The analysis in this paper is guided by a theoretical framework of technology adoption under partial population exposure proposed by Diagne and Demont (2007).
